Will Tesla Stock Go Up In 2026?
EV giant Tesla (NASDAQ:TSLA) has, somewhat surprisingly, undershot the broader…
Sell
17
SNN Quote, Financials, Valuation and Earnings
Last price:
$32.22
Seasonality move
:
6.32%
Day range:
$32.26 - $32.64
52-week range:
$23.69 - $38.79
Dividend yield:
2.34%
P/E ratio:
29.08x
P/S ratio:
2.40x
P/B ratio:
3.44x
Volume:
804K
Avg. volume:
575.4K
1-year change:
27.81%
Market cap:
$13.9B
Revenue:
$5.8B
EPS (TTM):
$1.13
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
$1.5B | -- | -- | -- | $36.63 |
|
AUTL
Autolus Therapeutics Plc
|
$21.3M | -$0.23 | 84624.25% | -288.08% | $9.52 |
|
AZN
AstraZeneca PLC
|
$14.8B | $1.13 | 4.6% | 128.14% | $98.96 |
|
BCYC
Bicycle Therapeutics Plc
|
$8.2M | -$1.07 | 92.62% | -25.75% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
$32.63 | $36.63 | $13.9B | 29.08x | $0.30 | 2.34% | 2.40x |
|
AUTL
Autolus Therapeutics Plc
|
$1.61 | $9.52 | $428.5M | -- | $0.00 | 0% | 8.36x |
|
AZN
AstraZeneca PLC
|
$89.83 | $98.96 | $278.5B | 29.83x | $0.52 | 1.74% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
$7.45 | $21.50 | $516.8M | -- | $0.00 | 0% | 18.21x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$4.75 | $17.94 | $2.9M | -- | $0.00 | 0% | 0.73x |
|
NCNA
NuCana Plc
|
$3.72 | $104.00 | $15.5M | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
36.96% | 0.432 | -- | 1.40x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 3.892 | 74.96% | 4.83x |
|
AZN
AstraZeneca PLC
|
41.56% | 0.163 | 13.71% | 0.66x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 2.129 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.246 | -- | 1.20x |
|
NCNA
NuCana Plc
|
0.52% | -0.585 | 0.95% | 4.03x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew plc
|
-- | -- | 5.7% | 9.2% | -- | -- |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
AZN
AstraZeneca PLC
|
$11.2B | $3.6B | 12.62% | 22.01% | 23.52% | $3.5B |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
Smith & Nephew plc vs. Competitors
-
Which has Higher Returns SNN or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to Smith & Nephew plc's net margin of -373.3%. Smith & Nephew plc's return on equity of 9.2% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About SNN or AUTL?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 12.26%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.52 which suggests that it could grow by 491.44%. Given that Autolus Therapeutics Plc has higher upside potential than Smith & Nephew plc, analysts believe Autolus Therapeutics Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is SNN or AUTL More Risky?
Smith & Nephew plc has a beta of 0.635, which suggesting that the stock is 36.528% less volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.013, suggesting its more volatile than the S&P 500 by 101.348%.
-
Which is a Better Dividend Stock SNN or AUTL?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.34%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or AUTL?
Smith & Nephew plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. Smith & Nephew plc's net income of -- is lower than Autolus Therapeutics Plc's net income of -$78.6M. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.08x while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.40x versus 8.36x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.40x 29.08x -- -- AUTLAutolus Therapeutics Plc8.36x -- $21.1M -$78.6M
-
Which has Higher Returns SNN or AZN?
AstraZeneca PLC has a net margin of -- compared to Smith & Nephew plc's net margin of 16.69%. Smith & Nephew plc's return on equity of 9.2% beat AstraZeneca PLC's return on equity of 22.01%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B AZNAstraZeneca PLC73.89% $0.81 $78.6B -
What do Analysts Say About SNN or AZN?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 12.26%. On the other hand AstraZeneca PLC has an analysts' consensus of $98.96 which suggests that it could grow by 10.16%. Given that Smith & Nephew plc has higher upside potential than AstraZeneca PLC, analysts believe Smith & Nephew plc is more attractive than AstraZeneca PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 AZNAstraZeneca PLC8 1 0 -
Is SNN or AZN More Risky?
Smith & Nephew plc has a beta of 0.635, which suggesting that the stock is 36.528% less volatile than S&P 500. In comparison AstraZeneca PLC has a beta of 0.315, suggesting its less volatile than the S&P 500 by 68.471%.
-
Which is a Better Dividend Stock SNN or AZN?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.34%. AstraZeneca PLC offers a yield of 1.74% to investors and pays a quarterly dividend of $0.52 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. AstraZeneca PLC pays out 66.98% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or AZN?
Smith & Nephew plc quarterly revenues are --, which are smaller than AstraZeneca PLC quarterly revenues of $15.1B. Smith & Nephew plc's net income of -- is lower than AstraZeneca PLC's net income of $2.5B. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.08x while AstraZeneca PLC's PE ratio is 29.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.40x versus 4.83x for AstraZeneca PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.40x 29.08x -- -- AZNAstraZeneca PLC4.83x 29.83x $15.1B $2.5B
-
Which has Higher Returns SNN or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to Smith & Nephew plc's net margin of -503.67%. Smith & Nephew plc's return on equity of 9.2% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About SNN or BCYC?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 12.26%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 188.59%. Given that Bicycle Therapeutics Plc has higher upside potential than Smith & Nephew plc, analysts believe Bicycle Therapeutics Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is SNN or BCYC More Risky?
Smith & Nephew plc has a beta of 0.635, which suggesting that the stock is 36.528% less volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.475, suggesting its more volatile than the S&P 500 by 47.505%.
-
Which is a Better Dividend Stock SNN or BCYC?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.34%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BCYC?
Smith & Nephew plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. Smith & Nephew plc's net income of -- is lower than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.08x while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.40x versus 18.21x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.40x 29.08x -- -- BCYCBicycle Therapeutics Plc18.21x -- $11.7M -$58.7M
-
Which has Higher Returns SNN or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About SNN or BDRX?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 12.26%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 3644.24%. Given that Biodexa Pharmaceuticals Plc has higher upside potential than Smith & Nephew plc, analysts believe Biodexa Pharmaceuticals Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is SNN or BDRX More Risky?
Smith & Nephew plc has a beta of 0.635, which suggesting that the stock is 36.528% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.955, suggesting its less volatile than the S&P 500 by 4.507%.
-
Which is a Better Dividend Stock SNN or BDRX?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.34%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BDRX?
Smith & Nephew plc quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than Biodexa Pharmaceuticals Plc's net income of --. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.08x while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.40x versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.40x 29.08x -- -- BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns SNN or NCNA?
NuCana Plc has a net margin of -- compared to Smith & Nephew plc's net margin of --. Smith & Nephew plc's return on equity of 9.2% beat NuCana Plc's return on equity of -286.82%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew plc-- -- $8.8B NCNANuCana Plc-- -$0.13 $35.1M -
What do Analysts Say About SNN or NCNA?
Smith & Nephew plc has a consensus price target of $36.63, signalling upside risk potential of 12.26%. On the other hand NuCana Plc has an analysts' consensus of $104.00 which suggests that it could grow by 559039.79%. Given that NuCana Plc has higher upside potential than Smith & Nephew plc, analysts believe NuCana Plc is more attractive than Smith & Nephew plc.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew plc1 3 0 NCNANuCana Plc0 1 0 -
Is SNN or NCNA More Risky?
Smith & Nephew plc has a beta of 0.635, which suggesting that the stock is 36.528% less volatile than S&P 500. In comparison NuCana Plc has a beta of 1.595, suggesting its more volatile than the S&P 500 by 59.472%.
-
Which is a Better Dividend Stock SNN or NCNA?
Smith & Nephew plc has a quarterly dividend of $0.30 per share corresponding to a yield of 2.34%. NuCana Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew plc pays 76.28% of its earnings as a dividend. NuCana Plc pays out -- of its earnings as a dividend. Smith & Nephew plc's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or NCNA?
Smith & Nephew plc quarterly revenues are --, which are smaller than NuCana Plc quarterly revenues of --. Smith & Nephew plc's net income of -- is lower than NuCana Plc's net income of -$378.9K. Notably, Smith & Nephew plc's price-to-earnings ratio is 29.08x while NuCana Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew plc is 2.40x versus -- for NuCana Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew plc2.40x 29.08x -- -- NCNANuCana Plc-- -- -- -$378.9K
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
What Are the Best AI Power Stocks?
As the construction of AI infrastructure accelerates, the gap between…
Is IONQ The Best Quantum Stock to Buy?
Riding a wave of investor enthusiasm for the technology, quantum…
Stock Ideas
Sell
47
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 60x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
73
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 39x
Alerts
Buy
80
FEIM alert for Dec 15
Frequency Electronics, Inc. [FEIM] is down 3.51% over the past day.
Buy
57
MOD alert for Dec 15
Modine Manufacturing Co. [MOD] is up 1.79% over the past day.
Sell
42
OKLO alert for Dec 15
Oklo, Inc. [OKLO] is down 5.81% over the past day.
